We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$9.03B
AUM Growth
+$6.6B
Cap. Flow
+$1.53B
Cap. Flow %
16.94%
Top 10 Hldgs %
64.29%
Holding
5,395
New
546
Increased
3,017
Reduced
1,240
Closed
466

Sector Composition

Rank Sector Weight
1 Technology 6.25%
2 Industrials 4.6%
3 Consumer Discretionary 4.31%
4 Healthcare 4.26%
5 Financials 3.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RDI icon
4726
Reading International Class A
RDI
$34.5M
$1K ﹤0.01%
296
-4,344
-94% -$17.6K
RNGR icon
4727
Ranger Energy Services
RNGR
$399M
$1K ﹤0.01%
428
-348
-45% -$975
RVPH
4728
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$1K ﹤0.01%
5
SCHV
4729
Schwab US Large-Cap Value ETF
SCHV
$16.1B
$1K ﹤0.01%
30
-136,149
-100% -$2.38M
SGU icon
4730
Star Group
SGU
$417M
$1K ﹤0.01%
83
-4,296
-98% -$40K
SIVR icon
4731
abrdn Physical Silver Shares ETF
SIVR
$4.48B
$1K ﹤0.01%
32
SLS icon
4732
SELLAS Life Sciences
SLS
$2.17B
$1K ﹤0.01%
460
-1,272
-73% -$3.48K
SUP
4733
DELISTED
Superior Industries International
SUP
$1K ﹤0.01%
+976
New +$1.54K
TK icon
4734
Teekay
TK
$990M
$1K ﹤0.01%
557
-34,056
-98% -$83.6K
TRMD icon
4735
TORM
TRMD
$2.94B
$1K ﹤0.01%
188
+88
+88% +$636
USAS
4736
Americas Gold and Silver
USAS
$1.73B
$1K ﹤0.01%
+225
New +$1.66K
VFL
4737
DELISTED
abrdn National Municipal Income Fund
VFL
$1K ﹤0.01%
+100
New +$1.27K
VRDN icon
4738
Viridian Therapeutics
VRDN
$2.62B
$1K ﹤0.01%
+158
New +$2.35K
WLKP icon
4739
Westlake Chemical Partners
WLKP
$760M
$1K ﹤0.01%
41
-358
-90% -$7.1K
XLF icon
4740
State Street Financial Select Sector SPDR ETF
XLF
$59.1B
$1K ﹤0.01%
37
-669,024
-100% -$16.3M
YHGJ icon
4741
Yunhong Green CTI Ltd
YHGJ
$8.98M
$1K ﹤0.01%
+52
New +$1.09K
YYY icon
4742
Amplify CEF High Income ETF
YYY
$743M
$1K ﹤0.01%
100
SER icon
4743
Serina Therapeutics
SER
$41.2M
$1K ﹤0.01%
43
-174
-80% -$6.21K
UFOX
4744
Defiance Space and Connective Tech ETF
UFOX
$892M
$1K ﹤0.01%
36
-3,205
-99% -$91.9K
ORKA
4745
Oruka Therapeutics
ORKA
$6.21B
$1K ﹤0.01%
+13
New +$917
VIRX
4746
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1K ﹤0.01%
215
-2,033
-90% -$17.8K
PIXY
4747
DELISTED
ShiftPixy, Inc. Common Stock
PIXY
0
AINC
4748
DELISTED
Ashford Inc.
AINC
$1K ﹤0.01%
102
-205
-67% -$1.51K
AVGR
4749
DELISTED
Avinger, Inc. Common Stock
AVGR
$1K ﹤0.01%
+14
New +$1.81K
CHIC
4750
DELISTED
Global X MSCI China Communication Services ETF
CHIC
$1K ﹤0.01%
35

Similar funds

Tower Research Capital (TRC)'s Q3 2020 Portfolio in Review

As of Q3 2020, Tower Research Capital (TRC) held 5,395 positions worth $9.03B, up 271% from $2.44B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Tower Research Capital (TRC) deployed $1.53B of net new capital in Q3 2020, opening 546 new positions and adding to 3,017 existing holdings. Its largest new stake was iShares Biotechnology ETF: 34,723 shares worth $4.7M.

By sector, the portfolio is most concentrated in Technology at 6.3% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Vanguard S&P 500 ETF, an estimated $38.5M trimmed.

  • Tower Research Capital (TRC)'s largest Q3 2020 buy was iShares Biotechnology ETF: 34,723 shares worth $4.7M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q3 2020, an estimated $487M increase.
  • Tower Research Capital (TRC)'s biggest Q3 2020 reduction was Vanguard S&P 500 ETF, cutting an estimated $38.5M.
  • Tower Research Capital (TRC) fully exited iPath Series B S&P 500 VIX Short-Term Futures ETN in Q3 2020, selling an estimated $51.8M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 64% of its $9.03B portfolio in Q3 2020.
  • Tower Research Capital (TRC) opened 546 new positions and closed 466 in Q3 2020.
  • Tower Research Capital (TRC)'s portfolio value rose 271% quarter-over-quarter to $9.03B.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2020, filed 16 Nov 2020.